BRAF and neoplasm: Gastrointestinal stromal tumors: BRAF V600E mutations are also found in 0.6 to 3.9% of gastrointestinal stromal tumors (GISTs), acting as tumor-agnostic markers predictive of response to BRAF inhibitors, similar to NTRK fusions [139].